Almirall relies on collaboration to accelerate its R&D process

R&D is at the heart of Almirall's strategy. The company's long-term growth is driven both by internal research work and by important partnerships forged with leading academic and scientific institutions. Thanks to these agreements, Almirall has become a recognised and trusted partner for both patients and the medical community.

The company has continued its commitment to partnerships in Medical Dermatology throughout 2022 to advance its Noble Purpose of transforming patients' lives. One of the most notable agreements this past year was the collaboration established with Evotec. The goal of this multi-target medical dermatology alliance is to discover and develop new therapies for severe skin diseases, including immune-mediated inflammatory conditions, such as atopic dermatitis, and non-melanoma skin cancer, such as basal cell carcinoma.

During the year, several agreements were signed with specialised companies and research centres with the aim of finding new solutions for people with skin diseases. In January, a research collaboration was initiated with the public centre IRB Barcelona, aimed at identifying new oral treatments for immuno-inflammatory dermatological diseases with unmet medical needs through the use of protein-degrading drugs that act as "molecular glues". In the same month, a multi-target licensing agreement with Ablexis and a research collaboration with AlivaMab Discovery Services, a leading company in the discovery and engineering of therapeutic antibodies, were also announced.

Almirall is also driving innovation in dermatology through Almirall SHINE, the company's new project to promote collaborations with centres of excellence. As part of this initiative, Almirall reached an agreement with the University of Michigan to accelerate understanding of the factors that trigger hidradenitis suppurativa. A research collaboration was also signed with the University of Dundee to develop a novel approach to chronic and debilitating dermatological diseases in which itching, or pruritus, plays a dominant role. Finally, Almirall announced an agreement with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), to advance treatment options for vitiligo.

All these collaborations enable Almirall to advance and generate scientific change and progress in the field of Medical Dermatology. By working with world-leading experts, the company is able to ensure innovation and design ground-breaking medicines that improve the lives of millions of people suffering from skin diseases.